EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Tumor–Platelet–Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities

Jalal Naghinezhad, Ehsan Kamali Yazdi, Ahmad Mohajerian, Negin Yousefi Chermehini, Pedram Ghanavati, Hamid Motamedi, Hadi Rezaeeyan

Expert Reviews in Molecular Medicine · 2026 · 28

DOI: 10.1017/erm.2026.10043 ↗
AbstractBibliografische Angaben

Abstract

Abstract Metastatic dissemination remains the leading cause of cancer-related mortality, driven not only by tumor-intrinsic factors but also by dynamic interactions within the tumor microenvironment (TME). Platelets and leukocytes orchestrate a systemic pro-metastatic network by shielding circulating tumor cells (CTCs), inducing neutrophil extracellular trap (NET) formation, and remodeling the extracellular matrix to prime pre-metastatic niches. This platelet-leukocyte crosstalk simultaneously promotes immune evasion, thromboinflammation, and metastatic seeding, creating a multi-cellular, temporally coordinated program that conventional anti-platelet and anti-inflammatory therapies inadequately target. Here, we propose a next-generation, multi-stimuli-responsive nanoparticle platform designed to disrupt these interconnected metastatic circuits. Engineered to respond to acidic pH in primary tumors and matrix metalloproteinases in pre-metastatic niches, these nanoparticles enable spatiotemporally controlled release of cytotoxic agents, anti-platelet drugs, and immune checkpoint inhibitors. Surface functionalization with anti-P-selectin further enhances specificity to tumor vasculature and facilitates platelet ‘hitchhiking’ for targeting CTCs. By simultaneously neutralizing platelet-leukocyte interactions, inhibiting NET-mediated scaffolds, and restoring anti-tumor immunity, this integrated strategy addresses multiple pro-metastatic mechanisms in a coordinated fashion. This work provides a conceptual and translational framework for precision anti-metastatic therapeutics, transforming the paradigm from single-pathway interventions to network-targeted strategies that disrupt tumor progression, CTC survival and metastatic niche formation. Our approach represents a critical step toward actionable, multi-modal interventions capable of preventing metastatic disease.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →